Malin-backed Altan sets sights on the US with painkiller drug
Irish biotech investor Malin Corporation owns around two-thirds of drug company; Malin’s chief business officer says only one other intravenous paracetamol currently available in US market, giving parent firm a potential exit
Altan, a drug company backed by Irish biotech investor Malin Corporation, is poised to enter the US market potentially providing its owner with an exit.
Irish stock exchange listed Malin owns about two-thirds of Altan, which last week announced it was seeking to have its intravenous paracetamol approved by US regulators. Malin’s chief business and financial officer Darragh Lyons said there was only one other IV paracetamol currently available in the US and Altan should...
Subscribe from just 1€
Choose the subscription that is right for you
For the first month
€19.99 Monthly ThereafterSubscribe today
For the first year
€199.99 annually thereafterSubscribe today
For the first 90 days
€55.00 quarterly ThereafterSubscribe today
These offers are not available for current subscribers. Offers and pricing are subject to change without notice.
Terms & Conditions Apply